Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Recursion Pharmaceuticals Inc Cl A (NQ: RXRX )

8.600 -0.040 (-0.46%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 10, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 7,288,336
Open 9.050
Bid (Size) 8.810 (5)
Ask (Size) 8.890 (98)
Prev. Close 8.640
Today's Range 8.220 - 9.340
52wk Range 4.920 - 16.75
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Demystifying Recursion Pharmaceuticals: Insights From 4 Analyst Reviews
Via Benzinga
RXRX Stock Earnings: Recursion Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024
RXRX stock results show that Recursion Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace

Performance

YTD
-12.87%
-12.87%
1 Month
+0.23%
+0.23%
3 Month
-14.77%
-14.77%
6 Month
+57.51%
+57.51%
1 Year
+59.26%
+59.26%

More News

Read More
Nvidia-Backed Recursion Pharmaceuticals Stock Is Up On Q1 Earnings: Everything You Need To Know
Via Benzinga
Nvidia Favorite SoundHound AI Delivers Beat-And-Raise Report
Via Investor's Business Daily
Topics Artificial Intelligence
Exposures Artificial Intelligence
Recursion Provides Business Updates and Reports First Quarter 2024 Financial Results
From Recursion Pharmaceuticals
Via GlobeNewswire
(RXRX) - Analyzing Recursion Pharmaceuticals's Short Interest
Via Benzinga
Where Will Recursion Pharmaceuticals Be in 5 Years?
Via The Motley Fool
Analyst Scoreboard: 5 Ratings For Recursion Pharmaceuticals
Via Benzinga
Clinical-Stage BioTech Drug Stocks Portfolio Jumped 7% In First Week Of May
Via Talk Markets
Recursion to Report First Quarter 2024 Business Updates and Financial Results on May 9
From Recursion Pharmaceuticals
Via GlobeNewswire
Recursion to Participate in Upcoming Investor Conferences
From Recursion Pharmaceuticals
Via GlobeNewswire
Altitude Lab Secures Small Business Administration Growth Fund Accelerator Grant to Launch Horizon, a Commercialization Partnering Program
From Recursion Pharmaceuticals
Via GlobeNewswire
Nvidia Owns a 3.4% Stake in This Innovative Artificial Intelligence (AI) Stock Cathie Wood Loves
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
The Top 3 Biotech Stocks to Buy in April 2024
Via InvestorPlace
3 Millionaire-Maker Biotech Stocks
Via The Motley Fool
Jim Cramer Says This Energy Stock Is 'Terrific,' Calls Casey's General Stores A 'Winner'
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Clinical-Stage BioTech Drug Stocks Portfolio Went Down 9% Last Week
Via Talk Markets
Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
Biotech on a Budget: 7 Stocks Under $10 With Huge Potential
Via InvestorPlace
Wall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for April 2024
Via InvestorPlace
The 10 Stocks In The Clinical-Stage BioTech Drug Stocks Index Are Down 4% YTD
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
Cathie Wood's Ark Invest Sells $20M+ Coinbase Shares As Bitcoin Trades Over $70K, Buys Palantir, Sells Nvidia Stock
Via Benzinga
Can Recursion Pharmaceuticals Stock Double in 5 Years? Here's What It Would Take.
Via The Motley Fool
The AI Advantage: 2 Healthcare Stocks at the Forefront of Innovation
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.